Morgan Stanley Downgrades Halozyme Therapeutics to Equal-Weight, Raises Price Target to $109
Benzinga Newsdesk 15 hours ago
Analyst RatingsNewsDowngradesPrice Target
Morgan Stanley analyst Vikram Purohit downgrades Halozyme Therapeutics (NASDAQ:HALO) from Overweight to Equal-Weight and raises the price target from $105 to $109.
Morgan Stanley analyst Vikram Purohit downgrades Halozyme Therapeutics (NASDAQ:HALO) from Overweight to Equal-Weight and raises the price target from $105 to $109.